Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 21 Other hematologic neoplasm 7 Head & Neck 5 Sarcoma 3 Tumor-Agnostic 2 CNS 2 Myeloid 1 Lymphoid 1 Genitourinary 1 Endocrine 1 Dermatologic 1

Conditions

Carcinoma, Renal Cell 1

Interventions

pembrolizumab 182 Magnetic Resonance Spectroscopy 161 Specimen Handling 134 enzalutamide 125 Nivolumab 118 Gemcitabine 96 Docetaxel 92 Radiosurgery 91 Prednisone 81 Androgen Antagonists 81 Abiraterone Acetate 79 Radiotherapy 75 apalutamide 66 Cisplatin 65 darolutamide 62 Ipilimumab 61 Biopsy 61 abiraterone 57 cabozantinib 55 Carboplatin 55 Leuprolide 52 enfortumab vedotin 50 Radiation 47 Pluvicto 45 Standard of Care 44 atezolizumab 41 Surveys and Questionnaires 38 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37 X-Rays 37 avelumab 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sorafenib × Genitourinary × 1 year × Clear all

NCT02184416 2026-02-27

ADONIS

Pfizer

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡